About Charles River Laboratories International Inc
- Industry: Life Sciences Tools & Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.criver.com/
Frequently Asked Questions
What is the 52-week range for CRL?
The 52-week high is $303.305 and the 52-week low is $146.2.
What is the P/E ratio for CRL?
The P/E ratio data is currently unavailable.
What is the dividend yield for CRL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -7.72%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -5.96%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.16.
Analyst Recommendation Trends
Wall Street analyst consensus for CRL over the last few months:
Latest CRL News
Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
Price targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revised margin goals. As you read on, you will see how to track these changes and what to watch as the...
Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory
Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Animal Model - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
Here is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15
UBS Reinstates Buy on Charles River, Announces $357 Price Target
UBS analyst Kevin Caliendo reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery
Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]
Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River
Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth.
AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Computer-Aided Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:
Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled
Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Experimental Animal Model Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp
Jefferies Maintains Buy on Charles River, Raises Price Target to $340
Jefferies analyst David Windley maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.
Is Charles River Laboratories Stock Outperforming the S&P 500?
Charles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin
Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320
Deutsche Bank analyst Justin Bowers maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.
TD Cowen Maintains Buy on Charles River, Raises Price Target to $325
TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330
Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322
RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.
Barclays Maintains Overweight on Charles River, Raises Price Target to $330
Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.
Charles River Laboratories: Positive Investor Day Is Fully Priced In
Charles River Laboratories has doubled over the past year, outperforming despite regulatory and AI-related concerns. Click for this CRL stock update.
Mizuho Maintains Neutral on Charles River, Raises Price Target to $295
Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.
Baird Maintains Outperform on Charles River, Raises Price Target to $334
Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch
Charles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be explained by its underlying cash generation. Recent moves to expand outsourced services in areas...
Why Charles River Laboratories (CRL) Stock Is Up Today
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.
Discover which S&P500 stocks are making waves on Thursday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day September 24, 2026 9:00 AM EDTCompany ParticipantsTodd Spencer - Corporate Vice...
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec
Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Contract Research Organization Services Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Market research report provides strategic analysis of a sector projected to reach USD 87.43 billion in
Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel
Opportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in emerging markets.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Safety Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The global Drug Safety Market research report examines growth trends, regulatory developments, technology adoption, and regional pharmacovigilance priorities. The market is projected t
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
WILMINGTON, Mass., September 24, 2026--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow
2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.
Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%
Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term financial targets
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to
Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI
Demand for outsourced pharmacokinetics services is rising, driven by AI, advanced bioanalysis, personalized medicine, biologics and complex global trials.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmacokinetics Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmacokinetics Services was estimated at US$853.5 Million in 2025 and is projected to reach US$1.4 Billion by 2032, growing at a CAGR of 7.8% from 2025 to 2032. Thi
3 Unpopular Stocks Walking a Fine Line
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Redraw Global Market Share
Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "In Vivo Toxicology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for In Vivo Toxicology was estimated at US$4.5 Billion in 2025 and is projected to reach US$6.0 Billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032. This comprehensive re
Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D ROI and Outsmart the Global Market
Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Outsourcing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Outsourcing was estimated at US$2.8 Billion in 2025 and is projected to reach US$4.5 Billion by 2032, growing at a CAGR
Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth and Outpace Disruption
Stricter safety rules and drug innovation are boosting demand, while high-throughput screening, predictive analytics, biomarkers, and non-animal methods create new opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Toxicology Testing Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Toxicology Testing Services was estimated at US$41.6 Billion in 2025 and is projected to reach US$59.8 Billion by 2032, growing at a CAGR of
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Disrupt Drug Discovery and Secure R&D ROI: Benchmark Fragment-Based Strategies from Astex, Evotec, Charles River, Schrödinger and Vernalis Through 2030
AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Fragment-based Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of
Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI
PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Patient Derived Xenograft / PDX Models - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b
Capitalize on the ADME-Toxicology Testing Shift: Benchmark Charles River, Thermo Fisher, Eurofins, WuXi AppTec and Evotec to Accelerate R&D ROI and Outpace Disruption
Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "ADME-Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for ADME-Toxicology Testing was valued at US$10 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR o
Charles River’s (CRL) Vaccine Push Meets A Bumpy Quarter
On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp/MVC to apply next-generation sequencing to MVC’s new multivalent enterovirus vaccine program. On its own, the deal is small. But it shows Charles River finding fresh uses for the sequencing technology it picked up through an earlier acquisition, and it lands […]
Charles River’s (CRL) New Automation Push Meets Old Margin Problems
On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and […]
Here’s Why This Strategy Decided to Exit Charles River Laboratories (CRL)
Riverwater Partners, an investment management company, released its ‘Sustainable Value Strategy’ Q2 2026 investor letter. The letter can be downloaded here. Small-cap stocks achieved their best first-half performance since 1991, with the Russell 2500 Value Index rising 17%, driven by the technology sector. The Sustainable Value Strategy underperformed its benchmark in the second quarter. The shortfall […]
Can Charles River Laboratories International (CRL) Justify Its Valuation On Its Rapid Cell Banking Launch?
Charles River Laboratories International (CRL) just rolled out rapid cell banking programs built around Next-Generation Sequencing and its Pathoquest acquisition, aiming to shorten development timelines for advanced therapies and strengthen quality and regulatory control. For context, Charles River Laboratories International has seen strong momentum build over the past few months, with a 90-day share price return of 52.25% and a 1-year total shareholder return of 79.42%. These figures point...
PGNY vs. CRL: Which Stock Is the Better Value Option?
PGNY vs. CRL: Which Stock Is the Better Value Option?
What Is Charles River Laboratories International (CRL) Signaling With Its Faster Cell Banking Platform?
Charles River Laboratories International (NYSE:CRL) unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools. The platform is designed to shorten biologics and advanced therapy cell bank lead times for biopharma clients while supporting regulatory readiness. Charles River states that the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The new rapid cell banking and release...
Charles River Laboratories International (CRL) Stock Fair Value Rises After Analysts Lift Targets
The analyst fair value estimate for Charles River Laboratories International has shifted from US$230.93 to US$282.43, a change of about 22% in the updated work. That move sits against Street commentary that now ranges from targets in the low US$200s to just above US$300. This reflects both renewed optimism around growth execution and ongoing discussion about valuation and timing. As you read on, you will see how this evolving price target story fits into the broader narrative and what signals...
What Charles River Laboratories International (CRL)'s Accelerated, NGS-Enabled Cell Banking Platform Means For Shareholders
Charles River Laboratories International has introduced rapid cell banking programs that shorten cell bank production timelines by about 40% versus the 20‑week industry standard, integrating rapid microbiological methods and CGMP-compliant Next-Generation Sequencing (NGS) to support faster, higher-quality biologic and advanced therapy development. An interesting aspect of this launch is its alignment with Charles River’s Alternative Methods Advancement Project, which aims to cut reliance on...
Why Charles River Laboratories (CRL) Stock Is Trading Up Today
Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 3.6% in the afternoon session after the company announced the launch of rapid cell banking programs designed to accelerate release timelines.
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
WILMINGTON, Mass., September 17, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehens
3 Reasons to Sell CRL and 1 Stock to Buy Instead
What a fantastic six months it’s been for Charles River Laboratories. Shares of the company have skyrocketed 79.5%, hitting $272.74. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) 2026 Global Healthcare Conference September 15, 2026 9:40 AM EDTCompany ParticipantsGlenn Coleman -...
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany...
Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus
FIGS, APH and MSFT post strong gains as Zacks upgrades and model portfolios spotlight stocks outperforming the broader market.
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
WILMINGTON, Mass., September 11, 2026--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320
Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
WILMINGTON, Mass., September 08, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity.
Health Care's Next Act: Tailwinds Emerging Across R&D Cycle
Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-25 | FOSTER JAMES C | -12,429 | - | - |
| 2026-08-25 | FOSTER JAMES C | -21,132 | - | - |
| 2026-08-25 | FOSTER JAMES C | -33,561 | $300 | $10,068,300 |
| 2026-08-25 | FOSTER JAMES C | +12,429 | $208.44 | $2,590,701 |
| 2026-08-25 | FOSTER JAMES C | +21,132 | $194.12 | $4,102,144 |
| 2026-08-19 | Girshick Birgit | -528 | - | - |
| 2026-08-19 | Parisotto Shannon M | -2,039 | - | - |
| 2026-08-19 | Parisotto Shannon M | -2,039 | $294.12 | $599,711 |
| 2026-08-19 | Parisotto Shannon M | +2,039 | $194.12 | $395,811 |
| 2026-08-18 | Andrews Nancy C | -573 | - | - |
| 2026-08-18 | Andrews Nancy C | -573 | $285.24 | $163,443 |
| 2026-08-18 | Andrews Nancy C | +573 | $164.3 | $94,144 |
| 2026-08-11 | Girshick Birgit | -6,500 | - | - |
| 2026-08-11 | Girshick Birgit | -6,500 | $279.9 | $1,819,350 |
| 2026-08-11 | Girshick Birgit | +6,500 | $179.66 | $1,167,790 |
| 2026-08-11 | Parisotto Shannon M | -3,714 | - | - |
| 2026-08-11 | Parisotto Shannon M | -3,714 | $279.66 | $1,038,657 |
| 2026-08-11 | Parisotto Shannon M | +3,714 | $179.66 | $667,257 |
| 2026-08-10 | LaPlume Joseph W | -257 | - | - |
| 2026-08-10 | FOSTER JAMES C | -28,733 | - | - |
| 2026-08-10 | FOSTER JAMES C | -28,733 | $275 | $7,901,575 |
| 2026-08-10 | FOSTER JAMES C | +28,733 | $179.66 | $5,162,171 |
| 2026-08-06 | Knell Michael Gunnar | -736 | - | - |
| 2026-08-06 | Knell Michael Gunnar | -1,205 | - | - |
| 2026-08-06 | Knell Michael Gunnar | -404 | - | - |
| 2026-08-06 | Knell Michael Gunnar | -736 | $258.53 | $190,278 |
| 2026-08-06 | Knell Michael Gunnar | -1,205 | $258.53 | $311,529 |
| 2026-08-06 | Knell Michael Gunnar | -404 | $258.53 | $104,446 |
| 2026-08-06 | Knell Michael Gunnar | +736 | $208.44 | $153,412 |
| 2026-08-06 | Knell Michael Gunnar | +1,205 | $194.12 | $233,915 |
| 2026-08-06 | Knell Michael Gunnar | +404 | $179.66 | $72,583 |
| 2026-08-06 | Knell Michael Gunnar | -482 | $265.17 | $127,812 |
| 2026-08-06 | Knell Michael Gunnar | -620 | $263.94 | $163,643 |
| 2026-08-06 | Knell Michael Gunnar | -213 | $262.37 | $55,885 |
| 2026-08-06 | Knell Michael Gunnar | -810 | $261.45 | $211,775 |
| 2026-08-06 | Knell Michael Gunnar | -901 | $260.63 | $234,828 |
| 2026-08-06 | Knell Michael Gunnar | -1,274 | $259.07 | $330,055 |
| 2026-08-06 | Creamer Victoria L | -4,179 | - | - |
| 2026-08-06 | Creamer Victoria L | -4,179 | $259.16 | $1,083,030 |
| 2026-08-06 | Creamer Victoria L | +4,179 | $179.66 | $750,799 |
| 2026-08-05 | Parisotto Shannon M | -5,046 | $263 | $1,327,098 |
| 2026-06-29 | FOSTER JAMES C | -75,000 | $225 | $16,875,000 |
| 2026-06-05 | FOSTER JAMES C | +10,000 | - | - |
| 2026-06-05 | FOSTER JAMES C | -10,000 | - | - |
| 2026-06-05 | FOSTER JAMES C | +20,000 | - | - |
| 2026-06-05 | FOSTER JAMES C | -20,000 | - | - |
| 2026-06-05 | FOSTER JAMES C | +153,361 | - | - |
| 2026-06-05 | FOSTER JAMES C | -153,361 | - | - |
| 2026-06-05 | Girshick Birgit | +3,386 | - | - |
| 2026-06-05 | Girshick Birgit | -3,386 | - | - |
| 2026-06-05 | Parisotto Shannon M | +1,529 | - | - |
| 2026-06-05 | Parisotto Shannon M | -1,529 | - | - |
| 2026-06-02 | Barg Steven | +422 | $174.79 | $73,761 |
| 2026-05-31 | Mintz Mark | -64 | $180.71 | $11,565 |
| 2026-05-31 | LaPlume Joseph W | -235 | $180.71 | $42,467 |
| 2026-05-31 | Knell Michael Gunnar | -48 | $180.71 | $8,674 |
| 2026-05-31 | Girshick Birgit | -378 | $180.71 | $68,308 |
| 2026-05-31 | Creamer Victoria L | -194 | $180.71 | $35,058 |
| 2026-05-31 | Parisotto Shannon M | -170 | $180.71 | $30,721 |
| 2026-05-30 | Mintz Mark | -305 | $180.71 | $55,117 |
| 2026-05-30 | LaPlume Joseph W | -744 | $180.71 | $134,448 |
| 2026-05-30 | Knell Michael Gunnar | -152 | $180.71 | $27,468 |
| 2026-05-30 | Girshick Birgit | -1,204 | $180.71 | $217,575 |
| 2026-05-30 | FOSTER JAMES C | -1,596 | $180.71 | $288,413 |
| 2026-05-30 | Creamer Victoria L | -616 | $180.71 | $111,317 |
| 2026-05-30 | Parisotto Shannon M | -551 | $180.71 | $99,571 |
| 2026-05-29 | Coleman Glenn | +6,640 | $180.71 | $1,199,914 |
| 2026-05-29 | Mintz Mark | +2,534 | $180.71 | $457,919 |
| 2026-05-29 | LaPlume Joseph W | +5,257 | $180.71 | $949,992 |
| 2026-05-29 | Knell Michael Gunnar | +1,837 | $180.71 | $331,964 |
| 2026-05-29 | Girshick Birgit | +9,961 | $180.71 | $1,800,052 |
| 2026-05-29 | Creamer Victoria L | +5,135 | $180.71 | $927,946 |
| 2026-05-29 | Parisotto Shannon M | +4,361 | $180.71 | $788,076 |
| 2026-05-27 | Creamer Victoria L | -148 | $156.73 | $23,196 |
| 2026-05-27 | Parisotto Shannon M | -105 | $156.73 | $16,457 |
| 2026-05-27 | Mintz Mark | -47 | $156.73 | $7,366 |
| 2026-05-27 | Girshick Birgit | -242 | $156.73 | $37,929 |
| 2026-05-27 | Knell Michael Gunnar | -37 | $156.73 | $5,799 |
| 2026-05-27 | LaPlume Joseph W | -185 | $156.73 | $28,995 |
| 2026-05-26 | Creamer Victoria L | -198 | $160.3 | $31,739 |
| 2026-05-26 | Parisotto Shannon M | -168 | $160.3 | $26,930 |
| 2026-05-26 | Mintz Mark | -64 | $160.3 | $10,259 |
| 2026-05-26 | Girshick Birgit | -376 | $160.3 | $60,273 |
| 2026-05-26 | Knell Michael Gunnar | -50 | $160.3 | $8,015 |
| 2026-05-26 | LaPlume Joseph W | -243 | $160.3 | $38,953 |
| 2026-05-12 | Andrews Nancy C | +3,964 | - | - |
| 2026-05-12 | Andrews Nancy C | -3,964 | - | - |
| 2026-05-08 | Barg Steven | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Thompson Craig B. | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Graves Paul W | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Ceesay Abraham | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | MACKAY MARTIN | +1,407 | $177.62 | $249,911 |
| 2026-05-08 | MACKAY MARTIN | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Andrews Nancy C | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Llado George Sr. | +450 | $177.62 | $79,929 |
| 2026-05-08 | Llado George Sr. | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Enyedy Mark J | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | Kemps-Polanco Reshema | +535 | $177.62 | $95,027 |
| 2026-05-08 | Kemps-Polanco Reshema | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | WILSON VIRGINIA M | +1,438 | $177.62 | $255,418 |
| 2026-05-08 | FOSTER JAMES C | +422 | $177.62 | $74,956 |
| 2026-05-08 | FOSTER JAMES C | +1,438 | $177.62 | $255,418 |
| 2026-05-01 | Coleman Glenn | +21,112 | $165.78 | $3,499,947 |
| 2026-03-04 | Girshick Birgit | -328 | - | - |
| 2026-03-03 | LaPlume Joseph W | +25 | $174.54 | $4,364 |
| 2026-03-02 | FOSTER JAMES C | +16,796 | $178.61 | $2,999,934 |
| 2026-02-06 | Parisotto Shannon M | +7,169 | - | - |
| 2026-02-06 | Parisotto Shannon M | -7,169 | - | - |
| 2026-01-30 | LaPlume Joseph W | -1,749 | $211.68 | $370,228 |
| 2026-01-30 | LaPlume Joseph W | +5,456 | - | - |
| 2026-01-30 | Creamer Victoria L | -1,296 | $211.68 | $274,337 |
| 2026-01-30 | Creamer Victoria L | +5,006 | - | - |
| 2026-01-30 | FOSTER JAMES C | -14,664 | $211.68 | $3,104,076 |
| 2026-01-30 | FOSTER JAMES C | +39,031 | - | - |
| 2026-01-30 | Girshick Birgit | -3,061 | $211.68 | $647,952 |
| 2026-01-30 | Girshick Birgit | +9,500 | - | - |
| 2026-01-30 | Knell Michael Gunnar | -526 | $211.68 | $111,344 |
| 2026-01-30 | Knell Michael Gunnar | +1,668 | - | - |
| 2026-01-30 | Mintz Mark | -655 | $211.68 | $138,650 |
| 2026-01-30 | Mintz Mark | +1,797 | - | - |
| 2026-01-30 | Parisotto Shannon M | -1,067 | $211.68 | $225,863 |
| 2026-01-30 | Parisotto Shannon M | +4,236 | - | - |
| 2025-11-06 | Knell Michael Gunnar | +2,926 | $170.88 | $499,995 |